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 37 
Abstract 38 
Despite widespread reports that intranasal application of oxytocin has an exuberant 39 
variety of behavioural effects, very little of the huge amounts applied intranasally appears to 40 
reach the CSF. However, peripheral concentrations are raised to supraphysiological levels, 41 
with likely effects on diverse targets including the gastrointestinal tract, heart and 42 
reproductive tract. The wish to believe in the effectiveness of intranasal oxytocin appears to 43 
be widespread, and needs to be guarded against with scepticism and rigor. Pre-registering 44 
trials, declaring primary and secondary outcomes in advance, specifying the statistical 45 
methods to be applied, and making all data openly available should minimise problems of 46 
publication bias and questionable post hoc analyses. Effects of intranasal oxytocin also need 47 
proper dose-response studies, and need to include controls for peripheral effects, by 48 
administering oxytocin peripherally and by blocking peripheral actions with antagonists. 49 
Reports in the literature of oxytocin measurements include many that have been made with 50 
discredited methodology. Claims that peripheral measurements of oxytocin reflect central 51 
release are questionable at best. 52 
 53 
Introduction  54 
More than 100 neuropeptides are expressed in different neuronal subpopulations. 55 
Whereas neurotransmitters are packaged in abundant small vesicles targeted to nerve endings, 56 
peptides are packaged in large vesicles that are relatively sparse, and which can be released 57 
from all compartments of a neuron. These vesicles carry a large cargo (~85,000 molecules of 58 
oxytocin) and peptides act at receptors with nanomolar affinity (1). Often, receptors are 59 
densely expressed at sites innervated by few fibres that contain the peptide ligand, indicating 60 
that neuropeptides are more like hormones than neurotransmitters, acting at sites distant from 61 
their point of release, with organisational and activational roles rather than roles in 62 
information processing per se (2). 63 
Some neuropeptides have a startling ability to evoke particular behaviours. Central 64 
injections of oxytocin trigger satiety and enhance sexual behaviour in animal models; in rats 65 
and sheep they can trigger maternal behaviour (3,4), in monogamous voles they facilitate pair 66 
bonding (5), and oxytocin-receptor deficient mice show disturbances in social behaviour. 67 
Recently, there has been a deluge of reports that oxytocin affects social behavior in 68 
humans when delivered as a nasal spray, and in some studies when delivered peripherally (6). 69 
Such effects have several possible explanations. Oxytocin might enter the CNS, mimicking 70 
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“neurohormonal” oxytocin release (2), or might act peripherally to indirectly affect 71 
behaviour, either via oxytocin receptors or vasopressin receptors activated at high 72 
concentrations of oxytocin. Other possibilities are that reported effects reflect methodological 73 
weaknesses, and post-hoc interpretation of outcomes with minimal statistical rigor. 74 
 75 
Oxytocin and the blood-brain barrier 76 
Most of the body’s oxytocin is stored in the posterior pituitary, which, in the adult rat, 77 
contains 0.5-1µg oxytocin and similar amounts of vasopressin. This gland contains the nerve 78 
endings of magnocellular neurons whose cell bodies lie in the hypothalamus, but it lies 79 
outside the blood-brain barrier, so peptide released from these endings readily enters the 80 
blood. The rat pituitary contains enough vasopressin to maintain the normal plasma 81 
concentration of 1pg/ml for 30 days, and a concentration of 10pg/ml, as seen during water 82 
deprivation, for three days (1).  83 
Between the blood and interstitial fluid of the body there is no barrier to the passage 84 
of peptides, so the distribution volume for oxytocin is much larger than the plasma volume 85 
(7). Oxytocin is stable in plasma (except in pregnancy, when oxytocinase is abundant), and is 86 
cleared from the blood via the kidneys and liver. In the rat, at i.v. doses of up to 500ng/kg, 87 
oxytocin disappears from the blood with a half-life of 3-8min (8). The half-life in CSF is 88 
longer: 28min in guinea pig (9), and 19min in rat (10). Oxytocin is thought to be cleared from 89 
CSF by a combination of flow into the subarachnoid space (11), and active transport into 90 
blood (12). 91 
In man, the pituitary oxytocin content (estimated by bioassay) is ~14IU (28µg) (13). 92 
Circulating concentrations are (as in the rat) ~1-10pg/ml, and the pharmacokinetics after i.v. 93 
injection fit a two-compartment model, with a distribution volume of ~33L, a distribution 94 
half-life of ~3min and an elimination half-life of ~20min (14). As in the rat, ~1% of oxytocin 95 
is excreted in urine (15). 96 
After entering the blood, oxytocin rapidly penetrates extravascular fluid, but does not 97 
cross the blood-brain barrier in appreciable amounts. In an early study, Ermisch et al. gave 98 
rats intracarotid injections of radiolabelled oxytocin: brain areas without an effective blood-99 
brain barrier extracted up to 30-fold more peptide than other brain regions, but oxytocin 100 
failed to penetrate deeper into the brain (16). Brain areas that lack a blood-brain barrier are 101 
encapsulated by glial and endothelial cells that form tight junctions, preventing passage of 102 
peptides both to deeper brain regions and from them. 103 
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The effectiveness of the blood-brain barrier for oxytocin was measured by Mens et 104 
al., who injected 5µg subcutaneously in rats, increasing plasma concentrations 500-fold to 105 
~38,600pg/ml (10). Increases in CSF were modest; concentrations increased from ~40pg/ml 106 
to ~150pg/ml. The authors calculated that just 0.002% of the injected oxytocin had reached 107 
the CNS after 10min, when CSF concentrations were maximal. 108 
 109 
Oxytocin penetration of the brain after intranasal administration 110 
Two routes have been proposed for the passage of peptides from nose to brain. The 111 
first postulates internalization of peptide into olfactory or trigeminal neurons, followed by 112 
axonal transport and exocytosis. There is doubt about whether peptides survive 113 
internalisation, and Born et al. dismissed this as requiring hours for substances to reach the 114 
brain by axonal transport (17). Oxytocin might pass through intercellular clefts into the 115 
subarachnoid space, but transport across the arachnoid membrane is not an important route 116 
for the entry of solutes into brain (18). The arachnoid is a multi-layered epithelium with tight 117 
junctions between cells of the inner layer that form an effective seal; valve-like villi project 118 
into the sagittal sinus through the dura and only allow CSF movement from the brain to 119 
blood. However, if vast amounts of peptide accumulate in the subarachnoid space, the 120 
concentration difference across the blood-brain barrier might support non-specific passage. 121 
The slow disappearance of oxytocin from blood after intranasal application suggests that 122 
large amounts reach an extravascular pool from which it slowly leaches into the circulation. 123 
Ang and Jenkins studied the brain penetration of radiolabelled vasopressin given i.v., 124 
and, importantly, measured how much label was still associated with intact peptide (19). 125 
Vasopressin, like oxytocin, is a nonapeptide with a sulphur bridge, differing in just two 126 
amino acids, and has similar bioavailability. Plasma vasopressin disappeared with the 127 
expected bi-exponential decay, while CSF levels of the label were maximal after 50min; this 128 
peak was <1% of that in plasma, and none of the label in CSF was associated with intact 129 
peptide. They also gave labelled vasopressin intranasally, sampling CSF and plasma 40min 130 
later. The concentration of label in CSF was ~5% of that in plasma, but whereas 16.5% of the 131 
label in plasma was associated with intact peptide, none of the label recovered from CSF was. 132 
Since then, six studies have measured CSF levels of oxytocin or vasopressin 133 
following intranasal application. Born et al. reported that, after giving 40IU (80µg) in man, 134 
CSF levels rose within 10min from ~5pg/ml to ~10pg/ml, increasing to ~20pg/ml at 60min 135 
(17). They administered, as a bolus, more than twice the pituitary vasopressin content, 136 
justifying this dose on the basis that most probably passes through the nose without being 137 
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absorbed. Estimating the CSF volume as 300ml, it seems that ~4.5ng of vasopressin reached 138 
the CSF: 0.005% of the given dose – assuming that the rise was due to administered peptide 139 
and not endogenous release triggered indirectly. 140 
Striepens et al.(20) measured CSF oxytocin in 11 patients given 24IU oxytocin 141 
intranasally. Whereas Born et al. saw an increase after 10min (albeit with vasopressin, at a 142 
larger dose) (17), Striepens et al. saw no increase at 45 or 60min. However, three patients 143 
sampled at 75min had CSF levels 64% higher than controls (at ~30pg/ml). In the same 144 
month, the authors submitted a paper on fMRI changes in subjects tested 30min after 145 
intranasal oxytocin (21). That paper does not cite the CSF data, or the fact that the fMRI 146 
measurements were made at times when CSF oxytocin was unchanged. 147 
Neumann et al. gave 20μg of oxytocin intranasally to rats (20 times the pituitary 148 
content) and found no change in CSF oxytocin after 45min (22). However, they found a 149 
doubling of oxytocin levels in microdialysates of brain regions collected at 30-60min, 150 
correlated with a four-fold rise in plasma. Intracranial microdialysis inevitably ruptures blood 151 
vessels around the probe, so these measurements might reflect local passage into the brain 152 
from damaged vessels. 153 
Dal Monte et al. gave 48IU oxytocin (~10µg/kg body weight) intranasally to 154 
macaques, using either a spray or nebuliser (23). These increased CSF oxytocin from 155 
~35pg/ml to ~90pg/ml after 40min. On the (very) conservative assumption that the CSF/ECF 156 
volume in the macaque is 40ml, then the additional content at this time is 2.2ng, 0.002% of 157 
the administered dose.  158 
Chang et al. gave 25IU oxytocin to two macaques, and reported a rise in CSF from 159 
~20 to ~50pg/ml at 35min (24). In a larger study, Modi et al. gave 24IU oxytocin (~5µg/kg 160 
body weight) to macaques by spray or aerosol; only the aerosol produced a significant 161 
increase in CSF (from ~20 to ~60pg/ml) (25). Again assuming a CSF volume of 40ml, the 162 
additional content at this time is 1.6ng - 0.003% of the administered dose. Both spray and 163 
aerosol raised plasma oxytocin levels. Intravenous administration of the same dose raised 164 
plasma levels to ~60,000pg/ml with no increase in CSF. 165 
All seven studies administered enormous amounts of peptide intranasally – in every 166 
case more than the pituitary content as a bolus – yet found only modest rises in CSF: two 167 
found no rise. At most, 0.005% of intranasally injected oxytocin reaches the CSF within an 168 
hour. Intranasal application achieves higher concentrations of peptide in blood than in CSF, 169 
and, as basal concentrations in plasma are lower than in CSF, the proportional change in 170 
blood is much greater. 171 
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 172 
How much oxytocin must enter the brain for a behavioral effect? 173 
Although intranasal application seems inefficient, doses of oxytocin that have become 174 
conventional in human studies all exceed the pituitary content of oxytocin. Thus, given that 175 
enormous amounts are given, the tiny rate of penetration might still allow biologically 176 
relevant amounts of peptide to enter the brain. If 24IU oxytocin were delivered as a bolus 177 
intravenously, the peak plasma concentration would exceed 1,400pg/ml, three orders of 178 
magnitude higher than physiological concentrations. 179 
Are these enormous intranasal doses enough to deliver effective concentrations of 180 
oxytocin into the brain? In lactating rats, suckling evokes bursts of action potentials in 181 
oxytocin cells that result in pulsatile oxytocin secretion, and this bursting is facilitated by 1-182 
2ng oxytocin i.c.v. (26). Effects on maternal behavior in the rat need much higher doses 183 
(~400ng) (4). Partner preference effects in voles require infusions of oxytocin at 10-100ng/h 184 
(5), and, to stimulate maternal behavior in sheep, it seems necessary to deliver 5μg i.c.v. (3). 185 
It is unsurprising that higher concentrations of oxytocin are needed for behavioral 186 
effects than for peripheral effects. As in most G protein-coupled receptors, agonist 187 
stimulation of oxytocin receptors leads to desensitization (27). Receptors at peripheral sites 188 
are exposed to much lower concentrations of oxytocin (1-10pg/ml), than receptors in the 189 
brain (1), so will be more sensitive to it. 190 
Thus 1ng oxytocin is the lowest i.c.v. dose shown to elicit a behavioural effect in 191 
animal studies, and 2ng induces expression of the immediate-early gene c-fos in rat brain 192 
regions where oxytocin receptors are expressed, including in the amygdala and 193 
hypothalamus. By contrast, intranasal application of 1µg oxytocin in rats produced no 194 
activation at these or any other sites in the forebrain (28) - and no activation in the olfactory 195 
bulb, the postulated primary target of interneuronal transfer of oxytocin. Maejima et al. 196 
reported that intranasal administration of a higher dose of oxytocin (10µg) activated Fos 197 
expression at the paraventricular nucleus, the area postrema and the dorsal motor nucleus of 198 
the vagus (29). The area postrema is outside the blood-brain barrier, and should not be 199 
accessible to oxytocin from the CSF. These same areas were also activated by oxytocin given 200 
systemically. 201 
 202 
Peripheral consequences of intranasal oxytocin 203 
Although intranasal applications deliver only modest rises in CSF concentrations, 204 
they produce large and prolonged increases in circulating oxytocin, to levels far above those 205 
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needed for physiological effects. Oxytocin receptors are widely distributed in the periphery: 206 
their presence on mammary tissue and uterus is well known, but there are many other sites of 207 
expression (30). Fifty years ago, intranasal oxytocin was commonly used to augment labor, 208 
using doses much lower than used lately, despite the high levels of pregnancy oxytocinase 209 
that must be overcome for oxytocin to exert a uterotonic effect. Hoover studied 1,806 women 210 
who had been given intranasal oxytocin during childbirth (31). Labor was stimulated by 1-4 211 
doses of 0.4-0.8IU given at 20-min intervals - a total of, at most, 3.2IU. Equivalent effects 212 
were achieved by intravenous infusion of 1-2mU/min, giving rise to the estimate that ~1% of 213 
intranasally-applied oxytocin enters the circulation (32). 214 
Intranasal application of oxytocin or vasopressin, at doses currently used, delivers 215 
supraphysiological concentrations into the circulation. Born et al. achieved plasma 216 
concentrations of 20pg/ml after giving 40IU vasopressin (17). These are higher than 217 
Robertson et al. reported for any patient, including those with pathologically elevated 218 
vasopressin secretion; in man, maximal urine concentrating ability is achieved at a 219 
vasopressin concentration of ~5pg/ml (33). Of the above-mentioned studies, four (20,22,24, 220 
25) achieved oxytocin concentrations in excess of 20pg/ml from basal levels of <5pg/ml, 221 
while Dal Monte et al. reported a rise to 80pg/ml after nasal spray, but no significant rise 222 
with a nebulariser (23). Modi et al. reported a 100-fold increase in plasma in the macaque (to 223 
>300pg/ml), and a rise to ~60pg/ml (from 10pg/ml) after nebulariser application (25). 224 
 225 
Peripheral targets for oxytocin 226 
Oxytocin regulates feeding and metabolism at multiple sites (34,35). Its receptors are 227 
expressed throughout the gastrointestinal tract, and on gastric vagal nerve endings (36). 228 
Intranasal application in dogs increases glucagon and insulin secretion (37), and this is 229 
probably mediated peripherally as intravenous oxytocin has a similar effect in goats (38) and 230 
dogs (39). In rats, oxytocin receptors are expressed by glucagon- and insulin-secreting cells 231 
in the pancreas (40), and direct stimulation of glucagon release has been characterised in vitro 232 
(41). Oxytocin also affects gastric motility: it is secreted in response to food intake, and slows 233 
gastric emptying (42). 234 
 At the ventromedial nucleus of the hypothalamus, oxytocin promotes both satiety and 235 
sexual receptivity – enhancing the lordosis effect in female rats (43); this nucleus contains 236 
virtually no oxytocin fibres so is a likely target of dendritic secretion from magnocellular 237 
oxytocin neurons (35). Some oxytocin cells of the paraventricular nucleus project to the 238 
spinal cord, where they regulate penile erection (44). However, oxytocin is also released from 239 
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the pituitary during sexual arousal, and, in the male reproductive tract, oxytocin acts on the 240 
vas deferens to facilitate sperm transport (45), in the prostate gland (46) to promote 241 
ejaculation, and on the penis (47) to promote erection. 242 
 Oxytocin receptors are expressed in the heart, coupled to secretion of natriuretic 243 
hormone (48). Oxytocin has direct cardiac effects, and intranasal application in man increases 244 
heart rate variability (49). At the anterior pituitary, oxytocin is a releasing factor for prolactin, 245 
and has effects on other endocrine cells too (50). In man, intravenous oxytocin has been 246 
reported to inhibit ACTH release (51), although in animal models oxytocin seems to have a 247 
predominantly stimulatory effect (52). Measurements of plasma corticosterone after 248 
intranasal oxytocin have reported mixed effects; one recent study reports a rise in stress-249 
evoked secretion (53). Oxytocin receptors are also present on bone (54) and in the thymus 250 
(55). Finally, oxytocin at moderately high concentrations is an agonist at V1 vasopressin 251 
receptors, and these are expressed at many peripheral sites (including the olfactory epithelium 252 
(56); the consequences of activating these is not known). These peripheral actions of oxytocin 253 
seem likely to have some behavioural consequences – especially those on reproductive 254 
organs, the heart and gastrointestinal tract.  255 
However, it is not impossible that enormous amounts of oxytocin delivered 256 
intranasally achieve biologically significant elevations in the brain. Oxytocin is avidly 257 
degraded in brain tissue, as known from the fact that CSF concentrations of oxytocin-258 
associated neurophysin are much higher than those of oxytocin. This neurophysin, a fraction 259 
of the peptide precursor, is secreted in equimolar amounts to oxytocin, but is not 260 
enzymatically degraded in brain. Comparing CSF levels of neurophysin and oxytocin 261 
suggests that only ~5% of the oxytocin that is released in the rat brain reaches the CSF (1). 262 
Thus, intranasally applied oxytocin might penetrate some brain regions yet not enter the CSF. 263 
However, it seems inappropriate to cite CSF measurements as if they demonstrate that 264 
substantial brain penetration occurs when they show minimal penetration at best, and it is 265 
disconcerting that the high levels of oxytocin achieved in the periphery are assumed to have 266 
no behavioral consequences. Effects of intranasal oxytocin need proper dose-response 267 
studies, and need to include controls for peripheral effects, by administering oxytocin 268 
peripherally and by blocking peripheral actions with antagonists. 269 
 270 
Measuring oxytocin and vasopressin 271 
Many studies have drawn conclusions from highly questionable measurements of 272 
plasma oxytocin, and others mistakenly claim that plasma measurements reliably reflect 273 
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oxytocin release in the brain. Validated radioimmunoassays have long converged on the 274 
conclusion that basal circulating levels of oxytocin and vasopressin in man are in the range 1-275 
10pg/ml, confirmed recently by combined LC/mass spectrometry (57). However, assays of 276 
unextracted plasma mainly measure immunoreactivity that is chemically and physiologically 277 
unrelated to vasopressin or oxytocin, and mainly contained in high molecular weight 278 
fractions. Robertson et al. showed that two radioimmunoassays for vasopressin yielded 279 
measurements in unextracted plasma that were at least two orders of magnitude greater than 280 
those inferred from other evidence, and which did not fluctuate in parallel with endogenous 281 
authentic vasopressin (33,58). Eliminating high molecular weight elements by extraction 282 
subsequently became standard in labs measuring oxytocin or vasopressin in plasma. 283 
However, many papers have used an ELISA on unextracted plasma, yielding values 284 
of >300pg/ml (59-65). In response to caustic criticism (66), the manufacturers “strongly 285 
recommended” that plasma samples should be extracted to avoid matrix interference (67), a 286 
recommendation reinforced by Christensen et al. (68), but this advice is still being ignored. 287 
Any hope that the measured levels correlate with authentic oxytocin levels seems vain. Three 288 
studies have compared ELISA oxytocin measurements of the same samples with and without 289 
extraction (69-71): all reported no correlations.  290 
One of those papers concludes that adolescent exposure to oxytocin increases plasma 291 
oxytocin in adulthood, and it might be expected that this conclusion was drawn from data on 292 
extracted plasma (70). Not so: the data from extracted samples showed no differences 293 
between groups: instead, the authors built their interpretation on the measurements of 294 
unextracted plasma. 295 
The discrepancy between measurements in unextracted and extracted plasma is two 296 
orders of magnitude, but when Wismer Fries et al. reported that urinary excretion of oxytocin 297 
and vasopressin in orphans was affected by early neglect, they reported levels that were, for 298 
both peptides, nearly a million fold too high, after applying a method that was neither 299 
sensitive enough or selective enough to measure either peptide in urine (72), a report that 300 
attracted pointed criticism (73,74). The authors have since improved their methodology, and 301 
in subsequent studies report values in line with classically validated measurements (75).  302 
 303 
Central and peripheral release of oxytocin 304 
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The lack of access to central measures of oxytocin has led some to turn to peripheral 305 
measures of oxytocin in the belief that these are convergent. Central oxytocin derives from at 306 
least three separate systems. Some magnocellular neurons project sparsely to some other 307 
brain areas, including the amygdala and septum, but it seems likely that most of the central 308 
innervations derives from non-neuroendocrine neurons of the paraventricular nucleus (76) 309 
that do not project to the pituitary. For example, oxytocin is released from neurons that 310 
project to the caudal brainstem, regulating gastric reflexes (77), and from neurons that project 311 
to the spinal cord which are involved in penile erection (44).  312 
Oxytocin is released into the brain in large amounts from the soma and dendrites of 313 
neurons that project to the pituitary– but this is semi-independent of axonal release, being 314 
governed in part by mobilisation of intracellular calcium, a mechanism  not present at the 315 
terminals (2). In response to α-melanocyte stimulating hormone (acting at MC4 receptors), 316 
oxytocin is released from dendrites of magnocellular neurons, but their electrical activity and 317 
peripheral oxytocin secretion is inhibited (78). In response to i.v. cholecystokinin, oxytocin is 318 
released into the blood and in the hypothalamus (79), but several other agents affect release 319 
differentially: for instance, in dogs, opioids stimulate peripheral secretion but suppress central 320 
secretion (80). Hyperosmotic stimuli increase oxytocin release from both dendrites and nerve 321 
terminals in rats, but on different time scales; dendritic release is increased as plasma 322 
concentrations fall (2). 323 
Appetite-related stimuli and some reproductive stimuli activate both central and 324 
peripheral oxytocin release, but the timings and extent of these actions differ, and differences 325 
are exaggerated by the different pharmacokinetics in the two compartments. Oxytocin is 326 
released into blood and brain during parturition, but in sheep (81), plasma concentrations 327 
were only elevated for 15min postpartum whereas those in CSF were increased for >120min.  328 
Stress affects both central and peripheral secretion of oxytocin– but while swim stress 329 
in rats increases oxytocin release in the hypothalamus and into plasma (82), novelty stress 330 
increases CSF but not plasma concentrations (83). In lactating rats, oxytocin is released in the 331 
hypothalamus in response to suckling before any peripheral secretion (84), but in guinea pigs, 332 
simultaneous measurements revealed a large increase in plasma during suckling but no 333 
change in CSF (85), leading the authors to conclude that CSF levels reflect secretion from 334 
centrally projecting neurons that are functionally independent of the magnocellular 335 
neurosecretory neurons. 336 
In lactating rhesus monkeys, Amico et al. (86) found that “variations in the 337 
concentrations of oxytocin in CSF were independent of the suckling stimulus and plasma 338 
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oxytocin concentrations” and noted, as others had before (87), that CSF levels but not plasma 339 
levels show a circadian variation. They concluded that “release of oxytocin into the CSF of 340 
lactating monkeys is disassociated from release into the peripheral circulation” (86).  341 
Winslow et al. measured CSF and plasma oxytocin in rhesus monkeys in a study of 342 
the effects of rearing conditions: while CSF oxytocin correlated with social behaviour, 343 
plasma levels did not, nor did they correlate with CSF levels collected in the same session 344 
(88). CSF and plasma concentrations showed no correlation in patients with aneurysmal 345 
subarachnoid haemorrhage (89), or in either suicide attempters or healthy volunteers (90), or 346 
in non-neurological and nonpsychiatric patients under basal conditions (91), or in MDMA 347 
users (92). Carson et al. reported that CSF and plasma oxytocin concentrations are correlated 348 
in children, but only after correcting the data for multiple variables that led to independent 349 
release (93). Oxytocin is released into the blood at orgasm in men (94), but Kruger et al. 350 
found no changes in CSF at any stage of the sexual response cycle (95). 351 
 352 
Publication bias  353 
Much of the interest in intranasal oxytocin followed a report that it enhanced trust 354 
(96); extravagant data interpretations and unorthodox uses of statistics in some of these 355 
studies have been incisively criticised (97), and such defects appear to be widespread. The 356 
unreliability of small clinical trials is recognised, and attributed to a combination of 357 
publication bias, questionable statistical analysis and methodological weaknesses, and there 358 
are similar concerns about basic biological research (98). Ferguson and Heene argued that for 359 
psychological research “ the field often constructs arguments to block the publication and 360 
interpretation of null results and that null results may be extinguished through questionable 361 
researcher practices”, resulting in the promulgation of theories that are “ideologically popular 362 
but have little basis in fact” (99). A survey of researchers in psychology suggested that 363 
practices such as excluding outliers post-hoc, using multiple outcome measures and only 364 
reporting results that reached statistical significance, and halting data collection to test for 365 
significance and resuming if significance is not found are common (100). Simmons et al. 366 
warned of practices that transform null findings into positive findings by statistical 367 
adjustments or the exercise of undisclosed “researcher degrees of freedom” (101), they 368 
showed, by simulations and experiments, how easy it is to accumulate “statistically 369 
significant” evidence for a false hypothesis.  370 
Pre-registering trials, declaring primary outcomes in advance, specifying statistical 371 
methods to be applied, and making data openly available should minimise these problems. 372 
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Several recent trials conform to some of these conditions, particularly in reporting clear 373 
primary outcomes. They show no effect of intranasal oxytocin on patients with schizophrenia 374 
or healthy volunteers (102,103); or in early psychosis (104); or on individuals with Prader-375 
Willi syndrome (105); or in MDMA users (92); or in youths with autism spectrum disorders 376 
(106,107). Revealingly, in the last study “caregivers who believed their children received 377 
oxytocin reported greater improvements than caregivers who believed their child received 378 
placebo.” The wish to believe in the effectiveness of intranasal oxytocin appears widespread, 379 
and needs to be guarded against. 380 
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